MMP-9-IN-14
MMP-9-IN-14 is a MMP-9 inhibitor (IC50 = 34.46 μM). MMP-9-IN-14 induces G1-phase cell cycle arrest and caspase-dependent apoptosis in cancer cells. MMP-9-IN-14 promotes the accumulation of phosphorylated γH2AX. MMP-9-IN-14 inhibits the migration and invasion of cancer cells, and downregulates the expressions of MMP-2, MMP-9 and hTERT in cancer cells. MMP-9-IN-14 inhibits tumor growth and angiogenic spread in animal models. MMP-9-IN-14 can be used for the research of cancers such as lung adenocarcinoma, cervical cancer and colorectal cancer.
For research use only. We do not sell to patients.
- Formula: C25H18Cl2N2O2S
- Molecular Weight:481.39
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
|
MMP-9 34.46 μM (IC50) |
Caspase 3 |
Caspase-7 |
MMP-2 |
In Vitro
MMP-9-IN-14 (Compound 24) (0.39-100 μM; 30 min, 37°C) directly inhibits the enzymatic activity of recombinant human MMP-9, with an IC50 of 34.46 μM[1].
MMP-9-IN-14 (0-50 μM; 72 h) inhibits the viability of various cell lines (A-549, H-226, H-460, HCT-116, Hep G2, HeLa, HaCaT, MRC-5), with IC50 values of 2.23, 2.34, 5.49, 4.95, 51.41, 2.75, 8.89, and 18.47 μM, respectively[1].
MMP-9-IN-14 (2.23 μM; 24-72 h) induces G1-phase cell cycle arrest in A-549 cells[1].
MMP-9-IN-14 (2.23 μM; 24-72 h) induces caspase-dependent apoptosis in A-549 cells[1].
MMP-9-IN-14 (2.23 μM; 24-72 h) increases the number of γH2AX-positive cells and induces the accumulation of DNA damage in A-549 cells[1].
Compound 24 (5-30 μM; 0-24 h) inhibits the migration and invasion of A-549 cancer cells[1].
Compound 24 (15-30 μM; 48 h) downregulates the expression of metastasis-related genes (MMP-2, MMP-9) and hTERT in A-549 cells, and potently inhibits TGF-β1-induced MMP expression[1].
Compound 24 (10-50 μM; 72 h) inhibits the proliferation of A-549 3D spheroids and exhibits anti-metastatic activity in physiologically relevant 3D models[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A-549 cells
-
Concentration:2.23 μM
-
Incubation Time:24 h, 48 h, 72 h
-
Result:Caused a significant decrease in the S-phase population after 24 h treatment. Induced cell accumulation in the G1 phase with a reduction in G2/M content by 48 h treatment.
Induced a marked G1-phase arrest, with ~65% of cells in G1 phase and concurrent reductions in S and G2/M fractions at 72 h treatment.
-
Cell Line:A-549,H-226,H-460,HCT-116,Hep G2,HeLa,HaCaT , MRC-5 cells
-
Concentration:0-50 μM
-
Incubation Time:72 h
-
Result:Inhibited the viability of various cell lines (A-549, H-226, H-460, HCT-116, Hep G2, HeLa, HaCaT, MRC-5), with IC50 values of 2.23, 2.34, 5.49, 4.95, 51.41, 2.75, 8.89, and 18.47, respectively.
-
Cell Line:A-549 cells
-
Concentration:2.23 μM
-
Incubation Time:24 h, 48 h, 72 h
-
Result:Caused a increase in apoptosis, with ~10% early apoptotic and ~8% late apoptotic cells after 24 h treatment.
Increased early apoptosis to ~11% and late apoptosis to ~15%, with ~70% cell viability remaining at 48 h treatment.
Increased caspase-3/7 activity by ~5-fold at 24 h, ~5-6-fold at 48 h, and ~7-fold at 72 h compared to controls.
-
Cell Line:A-549 cells
-
Concentration:5, 10, 15 μM
-
Incubation Time:0 h, 6 h, 12 h,
18 h, 24 h -
Result:Significantly and in a concentration-dependent manner inhibited cell migration and delayed wound closure.
-
Cell Line:A-549 cells
-
Concentration:15, 30 μM
-
Incubation Time:24 h
-
Result:Reduced the number of invading A-549 cells to ~65% of control levels at 15 μM. Reduced the number of invading cells to ~25% of control levelsat 30 μM.
-
Cell Line:A-549 cells (with or without TGF-β1 stimulation)
-
Concentration:15, 30 μM
-
Incubation Time:48 h
-
Result:Significantly suppressed TGF-β1-induced MMP-2 and MMP-9 mRNA expression: at 15 μM, MMP-2 expression was reduced by ~60% and MMP-9 by ~70% ; at 30 μM, both MMP-2 and MMP-9 mRNA levels were reduced to near baseline.
Downregulated hTERT expression: at 15 μM, hTERT expression was reduced by ~50%, and at 30 μM, was almost undetectable.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:A-549 Xenotransplantation chorioallantoic membrane (CAM) model[1]
-
Dosage:25 μM; 50 μM
-
Administration:topical; single administration
-
Result:Reduced median tumour area. Showed weaker, less homogeneous CellTracker Green signals in treated tumours, indicating reduced tumour cell viability/density.
Revealed a near-complete absence of disseminated fluorescent tumour cells in distal CAM regions, compared to frequent vasculotropic spread in vehicle controls.
Chemical Information
-
Molecular Weight 481.39
-
Formula C25H18Cl2N2O2S
-
SMILES
O=C(C1=CC=C(Cl)C=C1)CSC2=NC(C3=CC=C(Cl)C=C3)=CN2C4=CC=C(C(C)=O)C=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)